HR 1843 119th Congress House Health

To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.

Introduced: March 5, 2025 Introduced by: Dunn, Neal P. Republican · Florida See on congress.gov

Everywhere this bill has been 2 steps

Introduced

In committee

Reported out

Passed House

Passed Senate

To President

Became law

Mar 5, 2025

Referred to the House Committee on Energy and Commerce.

Mar 5, 2025

Introduced in House

Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

Plain-English summary Congressional Research Service

This bill requires the Food and Drug Administration (FDA) to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why). The FDA must also update or publish guidance on how it makes such determinations.

What's happening now March 5, 2025

Referred to the House Committee on Energy and Commerce.

Hearings & markups 1

Markup of Seven Bills
Markup Sep 17, 2025 · 10:00 AM EDT · Energy and Commerce Committee

Related & companion bills 4

Bill text 1 version

Introduced in House Formatted Text PDF Formatted XML

Source documents hosted by congress.gov.

Committees of jurisdiction 1

Energy and Commerce Committee
House of Representatives

Lobbying activity 59

Registered lobbyists who named this bill in their disclosure filings. Source: federal Lobbying Disclosure Act filings.

BLUE CROSS AND BLUE SHIELD OF KANSAS, INC.
for BLUE CROSS AND BLUE SHIELD OF KANSAS INC · Kansas · 2nd Quarter (Apr 1 - June 30) 2026
WHITMER & WORRALL, LLC
for CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · District of Columbia · 1st Quarter (Jan 1 - Mar 31) 2026
VIATRIS INC.
for VIATRIS INC · Pennsylvania · 1st Quarter (Jan 1 - Mar 31) 2026
ASSOCIATION FOR ACCESSIBLE MEDICINES
for ASSOCIATION FOR ACCESSIBLE MEDICINES · District of Columbia · 1st Quarter (Jan 1 - Mar 31) 2026
GUIDEWELL MUTUAL HOLDING CORPORATION
for GUIDEWELL MUTUAL HOLDING CORPORATION · Florida · 1st Quarter (Jan 1 - Mar 31) 2026
BLUE CROSS AND BLUE SHIELD OF FLORIDA, INC.
for BLUE CROSS AND BLUE SHIELD OF FLORIDA INC · Florida · 1st Quarter (Jan 1 - Mar 31) 2026

See all 59 filings →

Cosponsors 1

Mullin, Kevin

California · Mar 5, 2025

Cite this page click to expand

APA

U.S. Congress. (2026). H.R. 1843: To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.. 119th Congress. Open America. https://openamerica.io/bill/119-HR-1843/

MLA

"H.R. 1843: To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.." 119th Congress, 2026, Open America, https://openamerica.io/bill/119-HR-1843/.

Bluebook (legal)

H.R. 1843, 119th Cong. (2026), https://openamerica.io/bill/119-HR-1843/.

Markdown link

[H.R. 1843: To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.](https://openamerica.io/bill/119-HR-1843/)